Drs Wechsler and Akuthota discuss novel therapies in severe asthma treatment, including precision medicine, biomarkers, and new biologic agents.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969688). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Omalizumab https://reference.medscape.com/drug/xolair-omalizumab-343444

Mepolizumab https://reference.medscape.com/drug/nucala-mepolizumab-1000034

Bronchial Thermoplasty https://emedicine.medscape.com/article/2094272-overview

Eosinophilic Asthma and Sputum Eosinophilia https://www.webmd.com/asthma/eosinophilic-asthma-defined

Role of T2 Inflammation Biomarkers in Severe Asthma https://reference.medscape.com/medline/abstract/26574724

Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(21)00311-1

Dupilumab Prescribing Information https://www.regeneron.com/downloads/dupixent_fpi.pdf

FDA Approves Cinqair to Treat Severe Asthma https://www.fda.gov/news-events/press-announcements/fda-approves-cinqair-treat-severe-asthma

Benralizumab https://reference.medscape.com/drug/fasenra-benralizumab-1000213

Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) https://emedicine.medscape.com/article/333492-overview

Hypereosinophilic Syndrome https://emedicine.medscape.com/article/202030-overview

Anti-IL-5 Therapy in Patients With Severe Eosinophilic Asthma – Clinical Efficacy and Possible Criteria for Treatment Response https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0689-2

Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-blind, Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60988-X/fulltext

Allergic and Environmental Asthma https://emedicine.medscape.com/article/137501-overview

FDA Approves Maintenance Treatment for Severe Asthma https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma

Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma https://www.nejm.org/doi/full/10.1056/NEJMoa2034975

Efficacy and Safety of Itepekimab in Patients With Moderate-to-Severe Asthma https://www.nejm.org/doi/10.1056/NEJMoa2024257

The Targeted Eosinophil-Lowering Effects of Dexpramipexole in Clinical Studies https://www.sciencedirect.com/science/article/abs/pii/S107997961630328X

CRTH2 Antagonists in Asthma: Current Perspectives https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733922

Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) https://preciseasthma.org/preciseweb/

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype https://clinicaltrials.gov/ct2/show/NCT04718389